» Articles » PMID: 10442906

Risk Factors for Radiation Maculopathy and Papillopathy After Intraocular Irradiation

Overview
Journal Ophthalmology
Publisher Elsevier
Specialty Ophthalmology
Date 1999 Aug 12
PMID 10442906
Citations 42
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To evaluate rates of occurrence and risk factors for radiation maculopathy and radiation papillopathy in patients with choroidal melanoma at high risk for these complications.

Design: Cohort study.

Participants: A total of 558 patients treated with proton irradiation for choroidal melanoma between 1986 and 1996 with small to moderate sized tumors (less than 5 mm in height and 15 mm in diameter) located within 4 disc diameters of the macula or optic nerve and with a median ocular follow-up of 4 years.

Methods: Annual and cumulative rates of each endpoint were estimated using life table approaches. Prognostic factors were evaluated using the Cox proportional hazards regression.

Main Outcome Measures: Radiation maculopathy, radiation papillopathy, and vision loss to worse than 20/100.

Results: Cumulative 5-year rates for radiation maculopathy, radiation papillopathy, and vision loss were 64%, 35%, and 68%, respectively. Complication rates rose as a function of radiation exposure to the macula (P for trend = 0.04) or optic disc (P for trend < 0.001), although dose-response patterns were nonlinear. History of diabetes was a significant risk factor for maculopathy (P < 0.001) and optic neuropathy (P = 0.009).

Conclusions: The onset of radiation vasculopathy is determined primarily by the degree of irradiation exposure to the macula and optic disc. Risk may be enhanced among those with underlying vascular disorders.

Citing Articles

Radiation Retinopathy: Microangiopathy-Inflammation-Neurodegeneration.

Davids A, Pompos I, Kociok N, Heufelder J, Skosyrski S, Reichhart N Cells. 2025; 14(4).

PMID: 39996770 PMC: 11853965. DOI: 10.3390/cells14040298.


Efficacy and safety of proton radiotherapy in treating choroidal melanoma: a systematic review and meta-analysis.

Miao Y, Zheng T, Zhang Q, Li M, Lei Q, Liu Q Radiat Oncol. 2025; 20(1):7.

PMID: 39799332 PMC: 11724514. DOI: 10.1186/s13014-024-02580-w.


Personalized treatment approaches in intraocular cancer.

Liu Y, Rokohl A, Guo Y, Yao K, Fan W, Heindl L Adv Ophthalmol Pract Res. 2024; 4(3):112-119.

PMID: 38846623 PMC: 11154118. DOI: 10.1016/j.aopr.2024.03.005.


Radiation Optic Neuropathy: Management Options.

Oakey Z, Yesiltas Y, Singh A Ocul Oncol Pathol. 2023; 9(5-6):166-171.

PMID: 38089180 PMC: 10712985. DOI: 10.1159/000533426.


Outcomes after Proton Beam Irradiation in Patients with Choroidal Melanoma Eligible for Investigational AU-011 Treatment.

Wu F, Lane A, Trofimov A, Shih H, Gragoudas E, Kim I Ocul Oncol Pathol. 2023; 9(5-6):152-157.

PMID: 38089176 PMC: 10712974. DOI: 10.1159/000534184.